Presentation

Camurus is a Swedish biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies.

Recent highlights
In Q2, total revenues amounted to 227M SEK (+64%), whereof product sales were 225M SEK (+65%).
In January, Camurus announced dosing initiated in Ph3 trial of weekly setmelanotide in patients with genetic obesity disorder. The trial is expected to enroll 30 patients, with primary efficacy endpoint of proportion of patients with no weight gain. In May, Buvidal 160mg was launched in Australia after price and reimbursement approvals. In July, Camurus and Solasia entered into an agreement in which Solasia has acquired episil® oral liquid.

Outlook
Expected news flow by the end of 2022 includes first dosing in POSITANO Ph2b study in PLD, completed enrollment in CAM2029 Ph3 ACRO study, CHMP opinion for Buvidal in chronic pain, and initiation of Ph 3 de novo study CAM4072 (Rhythm).